Mega Lifesciences PCL (BKK:MEGA-F) Debt-to-Equity : 0.03 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL Debt-to-Equity?

Mega Lifesciences PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ฿159.95 Mil. Mega Lifesciences PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ฿173.23 Mil. Mega Lifesciences PCL's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ฿9,942.84 Mil. Mega Lifesciences PCL's debt to equity for the quarter that ended in Mar. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mega Lifesciences PCL's Debt-to-Equity or its related term are showing as below:

BKK:MEGA-F' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.14 Max: 0.27
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Mega Lifesciences PCL was 0.27. The lowest was 0.03. And the median was 0.14.

BKK:MEGA-F's Debt-to-Equity is ranked better than
88.77% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.295 vs BKK:MEGA-F: 0.03

Mega Lifesciences PCL Debt-to-Equity Historical Data

The historical data trend for Mega Lifesciences PCL's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL Debt-to-Equity Chart

Mega Lifesciences PCL Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.14

0.09

0.05

0.03

Mega Lifesciences PCL Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.05	0.03	0.03	0.03

Competitive Comparison of Mega Lifesciences PCL's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Lifesciences PCL's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mega Lifesciences PCL's Debt-to-Equity falls into.

Mega Lifesciences PCL Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mega Lifesciences PCL's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(119.778	+	132.058)	/	9302.162
	=	0.03

Mega Lifesciences PCL's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(159.945	+	173.227)	/	9942.841
	=	0.03

Mega Lifesciences PCL (BKK:MEGA-F) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mega Lifesciences PCL Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Lifesciences PCL (BKK:MEGA-F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA-F) » Definitions » Debt-to-Equity

Traded in Other Exchanges

MEGA:Thailand

Address

Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea,Bangna, Bangkok, THA, 10260

Website

https://www.megawecare.com

Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast-moving consumer goods as well as the provides distribution services relating to such products. The company's products portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purpose and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL (BKK:MEGA-F) Headlines

No Headlines